熊貓乳品(300898.SZ):調整募投項目投資優先順序
格隆匯11月25日丨熊貓乳品(300898.SZ)公佈,公司首次公開發行股票募集資金原計劃按輕重緩急投資蒼南年產3萬噸濃縮乳製品生產項目(擬投入募集資金3.20億元)、濟陽二期年產2萬噸濃縮乳製品項目(擬投入募集資金2.13億元)、營銷和應用中心項目(擬投入募集資金1977.05萬元)。
因實際募集資金淨額小於原擬投入募集資金總額,公司根據實際募集資金數額及各項目的輕重緩急等情況,調整並最終決定,將募集到的2.778億元資金優先投入到蒼南年產3萬噸濃縮乳製品生產項目的建設中;該項目建設完畢後募集資金仍有剩餘的,屆時將按照實際需求情況投入到濟陽二期年產2萬噸濃縮乳製品項目、營銷和應用中心項目兩個項目的建設中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.